NYRx Education & Outreach Month in Review Newsletter

December 2025

About the NYRx E&O Team

The NYRx E&O team serves as a liaison between all stakeholders and NYRx to support care coordination. Clinical liaisons are trained to support and help solve complex pharmacy cases for:

- Managed Care Plans
- Case workers and NYS agencies
- Prescribers and pharmacies with questions regarding NYRx drug coverage, prior approval requirements, and NYRx enrolled pharmacies
- Complex care coordination for populations such as HIV/AIDS, Hemophilia, Foster Care Children, Serious Mental Illness, Substance Use Disorder, and Hepatitis C

Updated NYRx E&O Publications

- NYRx Drug Class Coverage Overview: Antimigraine Agents
- NYRx Drug Class Coverage Overview: Antipsychotics – Second Generation
- NYRx Drug Class Coverage Overview: <u>Central Nervous System Stimulants</u> and Other Agents for Attention Deficit <u>Hyperactivity Disorder</u>
- NYRx Drug Class Coverage Overview: Constipation Agents
- NYRx Drug Class Coverage Overview: HIV PreExposure Prophylaxis Agents
- NYRx Drug Class Coverage Overview: Immunomodulators – Systemic and Benlysta
- NYRx Drug Class Coverage Overview: Sedative Hypnotics
- NYRx Notice to Prescribers: Coverage of Anti-Retroviral (ARV) Agents for HIV Treatment and HIV Pre-Exposure Prophylaxis (PrEP)

WELCOME!

As we wrap up the month of **November**, we'd like to highlight these activities from the past month. In this issue, you'll find links to new and updated information from NYRx Education & Outreach and the New York State Department of Health.

NEW & UPDATED PUBLICATIONS

NYRx Education & Outreach Publications

- NYRx Preferred Drug List Revised November 20, 2025
- NYRx Preferred Drug Quick List Revised November 20, 2025
- NYRx Clinical Criteria Update: Rybelsus® 3 mg Revised November 4, 2025
- NYRx Drug Coverage Overview: Wegovy® Effective November 20, 2025
- NYRx Drug Coverage Overview: Yeztugo® Effective November 6, 2025
- NYRx Cost Optimization Program Overview Effective December 18, 2025

New York State Department of Health Publications

- <u>Dialysis Clinic to Provide Phosphate Binders to Medicaid Members</u> Effective January 1, 2026
- <u>Backup Power Wheelchair Repairs</u> Power wheelchairs (PWC) will be eligible for use as a backup power wheelchair when new, primary PWC is provided.
- <u>eMedNY ProDUR/ECCA Provider Manual</u> Revised November 11, 2025
- Medicaid Practitioner Administered Drugs Update: CMS Cell and Gene Therapy (CGT) Access Model for Casgevy™ (exagamglogene autotemcel) and Lyfgenia® (lovotibeglogene autotemcel) — Effective January 1, 2026
- <u>Pediatric Planar Seating Frequency for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Providers</u> the frequency parameters for pediatric planar seating will be aligned to seating frequencies for adult wheelchairs effective January 1, 2026.
- <u>Preventative Maintenance for Power Wheelchairs</u> Preventative maintenance will be covered for all primary power wheelchairs (PWC) that are less than 5 years old effective January 1, 2026.
- Reimbursement for Wheelchair Evaluations Reimbursement for wheelchair evaluations using CPT code 97542 will be revised on or after January 1, 2026.

New York State Department of Health Press Releases

- Governor Hochul Signs Legislation to Eliminate Cost-Sharing on Asthma Inhalers
- New York State Department of Health Encourages New Yorkers to Get Flu Vaccine to Prevent Influenza-Associated Pediatric Deaths

MEET WITH THE TEAM

The NYRx E&O team is available to meet with you. Request a meeting.

<u>NYRx E&O Website</u>
<u>NYRx E&O Mailbox</u>
<u>NYRx E&O YouTube Channel</u>
<u>New York Public Health Now Podcast</u>

NYRx E&O Call Center 1-833-967-7310 M – F, 8:00 AM – 5:00 PM ET Excludes Holidays